Evidence map›Paper›PMID 18270836›Full record

SynthesisDigestive diseases and sciences2008

A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease.

Roja Rahimi, Shekoufeh Nikfar, Fatemeh Rahimi, Behzad Elahi, Saeed Derakhshani, Mohammad Vafaie, Mohammad Abdollahi

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 6 pooled it
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 6 syntheses or guidelines pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Crohn's disease.BMJ clinical evidence · 2011
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Review
  15. Article
  16. Gut microbiome and autoimmune disorders.Clinical and experimental immunology · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Roja RahimiPharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Shekoufeh Nikfar
Fatemeh Rahimi
Behzad Elahi
Saeed Derakhshani
Mohammad Vafaie
Mohammad Abdollahi
Tehran University of Medical Sciences · IRMinistry of Health and Medical Education · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate whether probiotics maintain remission in patients with Crohn's disease (CD).

designA meta-analysis of controlled clinical trials.

methodsPUBMED and Cochrane Central Register of Controlled Trials were searched for clinical trial studies investigated the efficacy of probiotics for the maintenance of remission in Crohn's disease. Clinical relapse and endoscopic relapse were the key outcomes of interest. Data were searched within the time period of 1966 through May 2007.

resultEight randomized placebo-controlled clinical trials met our criteria and were included in the analysis. Seven determined clinical relapse and three evaluated endoscopic relapse among patients with CD received probiotics for maintenance of remission. Pooling of seven trials for the outcome of clinical relapse yielded an odds ratio of 0.92 (95% confidence interval of 0.52-1.62, P = 0.8853), a nonsignificant odds ratio. The odds ratio for three studies for the outcome of endoscopic relapse was 0.97 (95% confidence interval of 0.54-1.78, P = 0.93), a nonsignificant odds ratio.

conclusionThis meta-analysis fails to demonstrate the efficacy of probiotics in maintaining remission and preventing clinical and endoscopic recurrence in CD. It is suggested to use probiotic preparations containing a mixture of lactobacillus with E. coli or Saccharomyces.

Indexed as

LactobacillusCrohn DiseaseHumansProbioticsRandomized Controlled Trials as TopicRemission InductionThoracoscopyTreatment Outcome

Identifiers

PMID18270836
OpenAlexW2055266605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.